Home » Newsletters » The Carlat Geriatric Psychiatry Report

The Carlat Geriatric Psychiatry Report

Dementia (Jan/Feb/Mar) | 2022

View Archived Issues

Introducing The Carlat Geriatric Psychiatry Report

January 1, 2022

Welcome to the inaugural issue of The Carlat Geriatric Psychiatry Report—our fifth CME newsletter. You’ve been asking for a source of unbiased reporting on geriatric psychiatry, and we’ve finally created one. We hope you’ll find it useful. Read More

Welcoming Our New Editor-in-Chief

January 1, 2022

It’s our pleasure to introduce Dr. Stephanie Collier, MD, MPH, as the editor-in-chief of CGPR. Dr. Collier is the director of education in the Division of Geriatric Psychiatry at McLean Hospital and an instructor in psychiatry at Harvard Medical School. Read More

CME Post-Test - Dementia, CGPR, January/February/March 2022

January 1, 2022

By successfully completing the test you will be awarded a certificate for 2 CME Credits. Read More

Learning Objectives, CGPR, Jan/Feb/March 2022, Dementia

April 28, 2022

After reading these articles, you should be able to… Read More

How to Interview the Older Patient

January 1, 2022

The expanding population of older adults has created a need for all clinicians to participate in their care. Interviewing techniques require adaptation in older adults, such as accounting for hearing or vision impairment and speaking slowly and clearly. This article will cover additional factors to consider when evaluating older patients. Read More

Aducanumab: What the FDA Approval Means for Clinicians

January 1, 2022

Aducanumab (Aduhelm), which is given intravenously once a month, is a monoclonal antibody directed against amyloid plaques that are associated with Alzheimer’s disease. The idea is that aducanumab will stick to the plaques in the brain. Once there’s an antibody on a plaque, the immune system signals the body’s defense mechanisms to remove it. Read More

How to Distinguish the Dementias

January 1, 2022

There are several types of dementia, and each has a different prognosis and treatment course. This article outlines Dr. Roca's approach for distinguishing between the most common varieties—Alzheimer’s, vascular, Lewy body, and frontotemporal. In addition, the article covers how to differentiate between mild and major neurocognitive disorder (NCD). Read More

Treating Dementia: An Approach From the United Kingdom

January 1, 2022

Although breaking the news to a patient or relative is challenging, discussing dementia often comes as a relief. A diagnosis helps explain why a patient is experiencing symptoms, and it opens the door to discuss expectations and management. We use a “person-centered approach” that focuses on a patient’s abilities, not their condition. Read More

Adlarity: A Second Cholinesterase Inhibitor Patch Is Approved

January 1, 2022

On March 14, 2022, Adlarity (donepezil hydrochloride) received FDA approval for the treatment of patients with mild, moderate, or severe Alzheimer’s dementia. Adlarity is as effective as other cholinesterase inhibitors. Read More